Skip to main content

Search

Study Title Study Sponsor Status Study Drug Trial Phase Study Protocol Number Site
The effects of alpha lipoic acid supplementation on nerve conduction study in patients with diabetic neuropathy EVA PHARMA Rejected ALPHA LIPOIC ACID 4 IRB-2022-5 King Fahad University Hospital (Al-Khobar)
Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis Pfizer Terminated Tafamidis 4 B3461001 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease Agios Pharmaceuticals, Inc. Ongoing Mitapivat 2/3 AG348-C-020 King Khalid University Hospital (Riyadh)
Prospective, observational study in sickle cell disease patients on crizanlizumab treatment in Middle East countries and India. Novartis Ongoing crizanlizumab 4 CSEG101AIC05 Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia
A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION Roche Ongoing ATEZOLIZUMAB (TECENTRIQ) 2 MO43156 King Fahad Specialist Hospital (Dammam)
A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory Novartis Saudi Limited Ongoing OAV101 (formerly AVXS-101) 3 COAV101B12301 King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)
Timing Of Thyroxine Dose In Ramadan KAIMRC Ongoing Levothyroxine 4 ICT22J/001 King Abdulaziz Medical City NG (Jeddah)
Fluids in septic shock (FISSH) KAIMRC Ongoing RINGER'S-LACTATE SOLUTION 3 SCT21R/001/01 King Abdulaziz Medical City NG (Riyadh)
Phase II study of neoadjuvant hormonal therapy guided by interval Ki67 testing in hormonal receptor-positive, HER2-negative breast cancer. King Abdullah Medical City (Makkah) Ongoing Letrozole (Femaplex) 2 20-718 King Abdullah Medical City (Makkah)
Modern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial Octapharma AG Ongoing Octanate, Wilate, Hemlibra, NovoSeven, Feiba 4 MOTIVATE King Abdulaziz Medical City NG (Riyadh)
View 91 - 100 From 712